89Zr-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients With Glioblastoma Multiforme

Completed 2 enrolled Memorial Sloan Kettering Cancer Center Weill Medical College of Cornell University · collab

NaSingle-groupOpen-labelDiagnostic

Summary

The purpose of this study is to test a new imaging agent called 89Zr-J591 (stands for humanized antibody called J591, that is attached to a radioactive material called Zirconium-89) in patients with glioblastoma multiforme.

Timeline

Start: 2015-04
Primary completion: 2018-08
Completion: 2018-08

Publications

McBriar JD, Shafiian N, Scharf S, Boockvar JA, Wernicke AG. Prostate-Specific Membrane Antigen Use in Glioma Management: Past, Present, and Future. Clin Nucl Med. 2024 Sep 1;49(9):806-816. doi: 10.1097/RLU.0000000000005365. Epub 2024 Jul 1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	huJ591	Monoclonal antibody	20 mg	—

89Zr-J591 Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody in Patients With Glioblastoma Multiforme

Summary

Timeline

Publications

Drugs

Indications